Interview With Oxana Megherea, PharmD, BCOP: SUCCESSOR-2 Trial, Mezigdomide, and More ASCO 2026 Highlights

Interview With Oxana Megherea, PharmD, BCOP: MajesTEC-9 trial, Teclistamab, and More ASCO 2026 Highlights

Interview With Samantha Shenoy, MSN, ACNP-BC: Navigating New Frontiers in CAR-T and Cellular Therapies

Welcome to the Multiple Myeloma Resource Center! Here you’ll find current information, news items, highlights from the literature, and other resources that focus on multiple myeloma and the advanced practitioner’s role in delivering high-quality care to our patients. We’re excited to provide this information to you and your colleagues and hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.


Charise Gleason, MSN, NP-C, AOCNP Winship Cancer Institute of Emory University Nell Hodgson Woodruff School of Nursing at Emory Healthcare	Amy Pierre, MSN, RN, ANP-BC Memorial Sloan Kettering Cancer Center Myeloma/Lymphoma Division Flatiron Health Real World Evidence Research Oncology

Ethical Challenges in CAR-T Slot Allocation

A Focus on Relapsed Multiple Myeloma

International Myeloma Working Group Immunotherapy Committee Consensus Guidelines and Recommendations for Optimal Use of T-Cell-Engaging Bispecific Antibodies In Multiple Myeloma

Role of the Clinical Pharmacist in Multiple Myeloma Management

International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma

Cureus

Rare extramedullary manifestations of multiple myeloma: a case series involving the thyroid, pleura, and skin

British Journal of Haematology

Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers

Blood Cancer Journal

Association between diabetic control and progression of monoclonal gammopathy of undetermined significance to multiple myeloma

Lancet

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial

Annals of Medicine and Surgery

Statin exposure after multiple myeloma diagnosis and risk of all-cause mortality, venous thromboembolism, pathological fractures, and acute kidney injury: a propensity score-matched retrospective cohort study

Clinica Chimica Acta; International Journal of Clinical Chemistry

Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders

New England Journal of Medicine

Teclistamab in multiple myeloma with one to three previous lines of therapy

US Food & Drug Administration

FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

Molecular and Cellular Probes

The role of RNA modifications in the pathological mechanisms and therapeutic targeting of multiple myeloma

Cancer Epidemiology

Occupational pesticide exposure and association of monoclonal gammopathy of undetermined significance in the Western Macroregion of Paraná

Multiple Myeloma Resource Center